Long-term follow-up of people with multiple myeloma treated with equecabtagene autoleucel
Follows people with multiple myeloma who previously received equecabtagene autoleucel over time.
Plain-language title generated from the registry record
Registry title: Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
Key facts
- Where
- Beijing, Tianjin, Wuhan, and Zhengzhou, ChinaSee the 6 sites
Where in China
- Peking University First HospitalBeijing, ChinaNot yet recruiting
- People's Hospital of Peking UniversitBeijing, ChinaNot yet recruiting
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical SciencesTianjin, ChinaTaking people
- Tianjin Medical University General HospitalTianjin, ChinaTaking people
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaNot yet recruiting
- Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou UniversityZhengzhou, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanjing IASO Biotechnology Co., Ltd.
- Trial code
- NCT07028970
- Record updated
- 19 June 2025
- Original description
This is a multicenter, open-label, single-arm, long-term follow-up clinical study. All patients who have received Equecabtagene Autoleucel Injection treatment will be enrolled.Read full original descriptionShow less
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
This is a multicenter, open-label, single-arm, long-term follow-up clinical study. All patients who have received Equecabtagene Autoleucel Injection treatment will be enrolled.
Inclusion: 1.Received Equecabtagene Autoleucel Injection treatment; 2.For those who participated in pre-marketing clinical studies or post-marketing real-world studies, must have completed or withdrawn from the original study; 3.Voluntary signing of an informed consent form approved by the ethics committee.
Exclusion: 1. Receipt of another lentiviral vector-based cell or gene therapy (either commercialized product or investigational product in a clinical tiral) between the infution of Equecabtagene Autoleucel Injection and the signing informed consent.